119 related articles for article (PubMed ID: 15078000)
1. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
[TBL] [Abstract][Full Text] [Related]
2. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Moine P; Cherbuliez C; Peytavin G; Fantin B; Köhler T
Antimicrob Agents Chemother; 2005 Mar; 49(3):1046-54. PubMed ID: 15728901
[TBL] [Abstract][Full Text] [Related]
3. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
[TBL] [Abstract][Full Text] [Related]
4. Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of Streptococcus pneumoniae.
Stein GE; Schooley S
Pharmacotherapy; 2002 May; 22(5):593-6. PubMed ID: 12013358
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.
Grohs P; Houssaye S; Aubert A; Gutmann L; Varon E
Antimicrob Agents Chemother; 2003 Nov; 47(11):3542-7. PubMed ID: 14576115
[TBL] [Abstract][Full Text] [Related]
6. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.
Chang WL; Kao CY; Wu CT; Huang AH; Wu JJ; Yang HB; Cheng HC; Sheu BS
Helicobacter; 2012 Jun; 17(3):210-5. PubMed ID: 22515359
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
8. [Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].
Kobayashi I; Kanayama A; Hasegawa M; Kaneko A
Jpn J Antibiot; 2013 Feb; 66(1):25-35. PubMed ID: 23777014
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Pawlak J; Belian B
Int J Antimicrob Agents; 2005 Jul; 26(1):81-4. PubMed ID: 15951159
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
Fukuda Y; Takahata M; Mitsuyama J
J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
[TBL] [Abstract][Full Text] [Related]
11. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics to combat resistance.
Woodnutt G
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
[TBL] [Abstract][Full Text] [Related]
13. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
Blondeau JM; Shebelski SD; Hesje CK
Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
17. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
[TBL] [Abstract][Full Text] [Related]
18. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
[TBL] [Abstract][Full Text] [Related]
20. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
